MedTrace Logo

Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

NCT04910802 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150000

Last updated 2021-09-16

No results posted yet for this study

Summary

The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.

Conditions

Interventions

BIOLOGICAL

Gardasil9

Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.

Sponsors & Collaborators

  • Karolinska University Hospital

    collaborator OTHER

  • Miriam Elfström

    lead OTHER_GOV

Principal Investigators

  • Joakim Dillner, MD, PhD · Karolinska University Hospital Laboratory

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
27 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910802 on ClinicalTrials.gov